Effect of bevacizumab on acetic acid–induced ulcerative colitis in rats
Yazarlar (7)
Tokat Gaziosmanpaşa Üniversitesi, Türkiye
Doç. Dr. Şeyma ÖZSOY
Tokat Gaziosmanpaşa Üniversitesi, Türkiye
Prof. Dr. Fikret GEVREK
Tokat Gaziosmanpaşa Üniversitesi, Türkiye
Hitit Üniversitesi, Türkiye
Tokat Gaziosmanpaşa Üniversitesi, Türkiye
| Makale Türü | Özgün Makale |
| Makale Alt Türü | SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale |
| Dergi Adı | Journal of Surgical Research |
| Dergi ISSN | 0022-4804 Wos Dergi Scopus Dergi |
| Dergi Tarandığı Indeksler | SCI |
| Dergi Grubu | Q4 |
| Makale Dili | İngilizce |
| Basım Tarihi | 08-2017 |
| Cilt No | 216 |
| Sayfalar | 191 / 200 |
| DOI Numarası | 10.1016/j.jss.2017.05.011 |
| Makale Linki | http://linkinghub.elsevier.com/retrieve/pii/S0022480417302652 |
| Özet |
| The aim of this study was to examine the effect of intraperitoneally administered bevacizumab on colitis induced by acetic acid. An experimental model of acetic acid-induced colitis was introduced in rats. After the induction of colitis, bevacizumab was administered intraperitoneally at two different daily doses of low (2.5 mg/kg) or high (5 mg/kg) concentration. Control groups were included for colitis and bevacizumab. After 7 d, the rats were sacrificed, and colonic tissues were harvested for macroscopic and microscopic examination of colonic damage. Tumor necrosis factor alpha, interleukin 1 beta (IL-1β), IL-6, myeloperoxidase, malondialdehyde, glutathione, and superoxidismutase values were measured biochemically. There was no statistically significant macroscopic improvement in damage to the colon tissues (P > 0.05). The severity of inflammation was significantly reduced (0.98 ± 0.22) in the low-dose bevacizumab-treated rat group compared with the control group (P < 0.001). The decrease in the inflammation score in the high-dose bevacizumab-treated rat group was not statistically significant (1.40 ± 0.33). In addition, although there was no significant change in the myeloperoxidase levels biochemically, IL-6 and malondialdehyde levels decreased in the low-dose treatment group (P = 0.014, P = 0.002, respectively). A significant decrease was found at both treatment doses in IL-1β (P < 0.001, P = 0.010), tumor necrosis factor alpha (P < 0.001, P = 0.015), superoxidismutase (P = 0.046, P = 0.011), and glutathione (P = 0.012 and P < 0.001) levels. Both treatment doses of bevacizumab were observed to have a protective effect in an experimental colitis model, and the dosage of 2.5 mg/kg bevacizumab was found to have a more prominent effect. |
| Anahtar Kelimeler |
| Ulcerative colitis | Bevacizumab | Treatment | Rats |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| WoS | 16 |
| Google Scholar | 24 |